Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (414)	8/16/2002 6:47:43 PM
From: tuck	Read Replies (1) \| Respond to of 513

>>NEEDHAM, Mass.--(BW HealthWire)--Aug. 16, 2002--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - News) announced today that its Board of Directors has authorized the repurchase of up to 2 million shares in AVANT common stock in the open market or through privately negotiated transactions through August 31, 2003. Under the program, shares may be repurchased from time to time and in such amounts as market conditions warrant, and subject to regulatory considerations. "The current valuation of AVANT stock makes repurchase of AVANT stock a solid investment and represents an attractive opportunity to enhance long-term shareholder value," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc.<< snip Cheers, Tuck